Table 1.
Compound | Marine Organism | Chemical Classes | Therapeutic Use | Ref. |
---|---|---|---|---|
Lurbinectedin | Tunicate | Alkaloid | Solid tumors | [32] |
Trabectedin | Tunicate | Alkaloid | Solid tumors | [33] |
Midostaurin | Tunicate/Actinobacteria | Indolocarbazole | Leukemias | [34] |
Plitidepsin ^ | Tunicate | Peptide | Multiple myeloma | [35] |
Belantamab mafodotin | Mollusk/Cyanobacteria | ADC/Peptide ** | Multiple myeloma | [36] |
Enfortumab vedotin | Mollusk/Cyanobacteria | ADC/Peptide * | Solid tumors | [37] |
Polatuzumab vedotin | Mollusk/Cyanobacteria | ADC/Peptide * | Lymphomas | [38] |
Brentuximab vedotin | Mollusk/Cyanobacteria | ADC/Peptide * | Lymphomas | [39] |
Eribulin mesylate | Sponge | Macrolide polyketide | Solid tumors | [40] |
Fludarabine phosphate | Sponge | Nucleoside | Leukemias, lymphomas | [41] |
Cytarabine | Sponge | Nucleoside | Leukemias, lymphomas | [42] |
Nelarabine | Sponge | Nucleoside | Leukemias, lymphomas | [43] |
ADC, antibody drug conjugate; ^, approved by the Australian Therapeutic Goods Administration; *, monomethyl auristatin E (MMAE) as payload; **, monomethyl auristatin F (MMAF).